Merck & Co., Inc. (MRK) Dividend History

Merck & Co., Inc. (MRK) is a global healthcare company specializing in pharmaceuticals, vaccines, and biologic therapies. Founded in 1891, it is known for developing innovative medicines across various therapeutic areas including oncology, infectious diseases, cardiology, and immunology. Merck focuses on research and development to improve health outcomes worldwide.

2000 Galloping Hill Road, Kenilworth, NJ, 07033
Phone: 908-740-4000
Dividend Yield: 3.77%
Dividend Frequency: Quarterly

Dividend History

Pay Date Amount Ex Dividend Date Record Date
October 07, 2025 $0.81 09/15/2025 09/15/2025
July 08, 2025 $0.81 06/16/2025 06/16/2025
April 07, 2025 $0.81 03/17/2025 03/17/2025
January 08, 2025 $0.81 12/16/2024 12/16/2024
October 07, 2024 $0.77 09/16/2024 09/16/2024
Show more

Dividends Summary

  • Merck & Co., Inc. has issued 88 dividend payments over the past 21 years
  • The most recent dividend was paid 42 days ago, on July 8, 2025
  • The first recorded dividend was paid on January 2, 2004
  • The highest dividend payout was $0.81 per share
  • The average dividend over this 21 year span is $0.50 per share
  • Merck & Co., Inc. has increased its dividend payments by 118.92% since 2004

Company News

  • Both Pfizer and Merck face challenges in their pharmaceutical businesses, including patent expirations and competitive pressures, but show potential for long-term recovery through innovative pipelines, cost-cutting measures, and attractive dividend yields.

    The Motley Fool
    Featured Companies: PFE
  • Ligand Pharmaceuticals completed a $460 million convertible senior notes offering due in 2030, using proceeds for general corporate purposes, stock repurchases, and hedge transactions to manage potential stock dilution.

    GlobeNewswire Inc.
    Featured Companies: AMGN LGND PFE
  • Merck, in collaboration with Pfizer and Astellas Pharma, announced successful Phase 3 trial results for Keytruda-Padcev combination therapy in muscle-invasive bladder cancer patients, showing significant improvements in survival outcomes.

    Benzinga
    Featured Companies: PFE
  • Merck reported Q2 2025 results with total sales of $15.8 billion, a 2% decrease from 2024. While KEYTRUDA sales grew 9%, vaccine sales declined significantly. The company beat EPS expectations and provided full-year guidance focusing on strategic acquisitions and cost savings.

    Investing.com
  • Merck's stock has underperformed the industry, sector, and S&P 500 this year due to various challenges, including the upcoming patent expiration of its blockbuster drug Keytruda in 2028 and declining sales of its Gardasil vaccine in China. However, the company has a promising pipeline and new products that could drive long-term growth.

    Zacks Investment Research
    Featured Companies: MRNA SMMT
Page data last updated 08/18/2025 14:55:36 UTC Dividend yield is calculated using only dividends that have already been paid. Future or declared dividends are not included